If you want to stick to the biotechs that have achieved revenue then NEU, PNV and TLX are all recent examples of biotechs that achieved high market caps before revenue.
If you want to stick to companies that managed this without any revenue then it is hard to go past IMU which made it into the ASX200 with a fully diluted MC of $4 billion a couple of years ago.
RAC is an unusual company, but it is far from unique on the ASX.
If you want to stick to the biotechs that have achieved revenue...
-
- There are more pages in this discussion • 330 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
-0.140(7.61%) |
Mkt cap ! $289.4M | |||
| Open | High | Low | Value | Volume |
| $1.88 | $1.89 | $1.70 | $456.4K | 259.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 8662 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |